{"name":"Nuvation Bio","slug":"nuvation","ticker":"NUVB","exchange":"NYSE","domain":"nuvationbio.com","description":"Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.","hq":"New York, NY","founded":0,"employees":"298","ceo":"David Hung, M.D.","sector":"Oncology","stockPrice":4.53,"stockChange":0.02,"stockChangePercent":0.44,"marketCap":"$1.6B","metrics":{"revenue":62902000,"revenueGrowth":633.1,"grossMargin":85.2,"rdSpend":115106000,"netIncome":-204627000,"cash":529211008,"dividendYield":0,"peRatio":-31.2,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2025-01-01","label":"Ibtrozi first approved","drug":"Ibtrozi","drugSlug":"taletrectinib","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-06-01","label":"Ibtrozi PHASE2 readout","drug":"Ibtrozi","drugSlug":"taletrectinib","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-12-01","label":"Ibtrozi PHASE2 readout","drug":"Ibtrozi","drugSlug":"taletrectinib","type":"phase3_readout","sentiment":"neutral"},{"date":"2034-06-01","label":"NUV-422 patent cliff ($0.0B at risk)","drug":"NUV-422","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"NUV-744 patent cliff ($0.0B at risk)","drug":"NUV-744","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AB-106","genericName":"AB-106","slug":"ab-106","indication":"Advanced solid tumors (Phase 2 development)","status":"phase_2"},{"name":"Ibtrozi","genericName":"TALETRECTINIB","slug":"taletrectinib","indication":"locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"AB-106, Itraconazole","genericName":"AB-106, Itraconazole","slug":"ab-106-itraconazole","indication":"Fungal infections","status":"phase_1"},{"name":"AB-106, Rifampicin","genericName":"AB-106, Rifampicin","slug":"ab-106-rifampicin","indication":"Tuberculosis","status":"phase_1"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"AB-106, digoxin","genericName":"AB-106, digoxin","slug":"ab-106-digoxin","indication":"Atrial fibrillation","status":"phase_1"}]}],"pipeline":[{"name":"AB-106","genericName":"AB-106","slug":"ab-106","phase":"phase_2","mechanism":"AB-106 is a TGF-β receptor inhibitor that blocks transforming growth factor-beta signaling to modulate immune responses and reduce fibrosis.","indications":["Advanced solid tumors (Phase 2 development)"],"catalyst":""},{"name":"Ibtrozi","genericName":"TALETRECTINIB","slug":"taletrectinib","phase":"marketed","mechanism":"Ibtrozi works by blocking the ROS1 protein, which is a genetic mutation found in some lung cancer cells.","indications":["locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC)"],"catalyst":""},{"name":"AB-106, Itraconazole","genericName":"AB-106, Itraconazole","slug":"ab-106-itraconazole","phase":"phase_1","mechanism":"Inhibits fungal cytochrome P450 14α-demethylase","indications":["Fungal infections"],"catalyst":""},{"name":"AB-106, Rifampicin","genericName":"AB-106, Rifampicin","slug":"ab-106-rifampicin","phase":"phase_1","mechanism":"Inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase","indications":["Tuberculosis"],"catalyst":""},{"name":"AB-106, digoxin","genericName":"AB-106, digoxin","slug":"ab-106-digoxin","phase":"phase_1","mechanism":"Digoxin inhibits the sodium-potassium ATPase pump.","indications":["Atrial fibrillation","Heart failure"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Nuvation Bio Announces FDA Clearance of IND for NUV-422","summary":"Nuvation Bio announced that the FDA has cleared the Investigational New Drug (IND) application for NUV-422, enabling the company to initiate a Phase 1 clinical trial.","drugName":"NUV-422","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Nuvation Bio Reports Third Quarter 2023 Financial Results","summary":"Nuvation Bio reported its financial results for the third quarter of 2023, with a focus on its pipeline and operational progress.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxNR0JjcDVYZHpyUG1Yc2RWcFpSS0luLW4yYnVfdTVnM2hwTHpHSlFxUnhoUS1GZUcwdmgyVHRrTWJWYkJMejVwa1NOTER6ZmxianJqRWhTY2Q1R093d25IUEU5OThNV1dDNGhOZlV1WlZMZkxXNlVPTDU0QllXU1NkS1JDZjZQVGJvSXJTbUxKUmRwSDJoUnN5ajJoMDZiQ1FCZ2k0Z2hoXzRkWThlMG1LeFdFY2l1UHA3dG9nUkYzd1VWYUVRMDl6V0x1REM3bUI2WjlTbk1YcXh4WTZw0gHiAUFVX3lxTE9IU0cxOV9rWElXeURZaHpSUWVialpTYmpaanQxWENpM05GbnJOQU9MZll6NlZoWEFwZjFfQTNaQ21XbVZiSXVqeF9wVXZfT3pxWDZyY2RFc1EzTWRuUWhuXzN0TFZQbHUtODgxWi04Rzd2ZUxNTE1iWnp4NzJfSTQ3OE5NRHh0V0U2UnIzUGY2RmtNV0pRdUd5MkNQdEg1ek5qUE1id1U5bnRFeXBLMUg0UDMyLVZiU0hFQnBvNG52QjVJY3dNTjRiQnRPYjN6VDJFV2ZTZkk2VGFpMlRFQmJRM1E?oc=5","date":"2026-04-06","type":"regulatory","source":"simplywall.st","summary":"A Look At Nuvation Bio (NUVB) Valuation As EMA Validates Taletrectinib Marketing Application - simplywall.st","headline":"A Look At Nuvation Bio (NUVB) Valuation As EMA Validates Taletrectinib Marketing Application","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-03","type":"regulatory","source":"simplywall.st","summary":"Is EMA Validation Of Taletrectinib Expanding Nuvation Bio’s (NUVB) Targeted Lung Cancer Opportunity? - simplywall.st","headline":"Is EMA Validation Of Taletrectinib Expanding Nuvation Bio’s (NUVB) Targeted Lung Cancer Opportunity?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQZE00cGtxR1hOcFpKWnNReEtXb2RWU1huWERpbG5WTE11M3Jyd2d6SHpoUFRSb21CZEJpNHJyNGQ0SUhpVkZJU25ZbHZuczBEZUhGd1ZDcUtIdWdGdWVqdUJRM3IwTzBUOWpJQTBycE9lNjBJWks2MEhsR3F0bHJ1Mkc1d2x3bzVxZzh2Y1FrdlU2enlFdUhNejBVMUJpTkJNYmtaRnpoQVV5R0M5dmtOSE02RWxhMWdBYkRtNDZSNG44SXpRR0hleHFFQWdYTWtzeFJHaQ?oc=5","date":"2026-03-29","type":"regulatory","source":"BioPharma APAC","summary":"Eisai And Nuvation Bio Advance Taletrectinib With EMA Validation For ROS1 Positive Lung Cancer - BioPharma APAC","headline":"Eisai And Nuvation Bio Advance Taletrectinib With EMA Validation For ROS1 Positive Lung Cancer","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-29","type":"regulatory","source":"simplywall.st","summary":"A Look At Nuvation Bio’s Valuation As EMA Validates Taletrectinib Application In Europe - simplywall.st","headline":"A Look At Nuvation Bio’s Valuation As EMA Validates Taletrectinib Application In Europe","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-19","type":"pipeline","source":"simplywall.st","summary":"Is It Time To Reassess Nuvation Bio (NUVB) After Its Recent Share Price Swings? - simplywall.st","headline":"Is It Time To Reassess Nuvation Bio (NUVB) After Its Recent Share Price Swings?","sentiment":"neutral"},{"date":"2026-03-02","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOQkZNYXlQLW03dEs0TjZiclVndmpLbGpSaUhNal9RSkhoT3hQMXdUQzNnc3dNUlJtaVV3M0wxMVlVVmY2b0l4YWtEYzY2VVg2dE5lZE80QzBoblA5bXFfMHJOOGxmWS13T2lIdTM0ZkNKZnRwZFV5Ym5CSXVUVjk2b2NvVQ?oc=5","date":"2026-01-17","type":"pipeline","source":"Yahoo Finance","summary":"Is Nuvation Bio (NUVB) Pricing In Its Sharp Swings Or A Long Runway For Growth - Yahoo Finance","headline":"Is Nuvation Bio (NUVB) Pricing In Its Sharp Swings Or A Long Runway For Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQcWo0Q0p4NjFUWTBEbFRJYVQ3WDFzLUJxcGt2b3N3MFBjWkdSVDdQcEwwM3BwTUROZGxUczdNNVBBTDRnRTdpUC0zVUZySFpwSUs4c3VMZzBLWlA2eWJhdWlGZDRiNzMwMFhxZFhxWmdPMjJVc3lZN3RkX2ZNRjBTSWE1cUFieVNlSWNnZmlkNHFBdDB2c09zQzcxYWZSNk1jeC1GdkRPVQ?oc=5","date":"2026-01-16","type":"deal","source":"The Pharma Letter","summary":"Eisai and Nuvation Bio ink licensing deal for taletrectinib - The Pharma Letter","headline":"Eisai and Nuvation Bio ink licensing deal for taletrectinib","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNdmprTFBBTC1nQWdjX25YeFpuX0tsWUF6NjZSNlVJTkxfYS1yUkttODZVWnVrcWsyM1VHQWVfR0Q1R3JVU2MwekF1MjZWNnI1THoxSFVUYnp2V09kVmU3bU5XQmdOUG80Rks0SXNPVXVHZEJWVW5hTFhDb3JlRVdhTUZBcmc?oc=5","date":"2026-01-16","type":"deal","source":"Yahoo Finance","summary":"A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal - Yahoo Finance","headline":"A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxQSEpreC0xZ3g2T0NMVGlZUUlYZFdSM0RfVjJ4YThRWjkxVFNDT0s4QTBLLUgyT2Z0THlJVGR4TldSTUVRMEV0VUlSSDJ2UmJfVnZNV01Oa0lXMUppcXdSSlg2VTU5Uk0wc2EwQmdRd2FaUXlPcndES1B4VnpkU05WLWQxQWVndFAxQ3RSM2JtUUhPNHROTUJELTA3N0Z5dlQ5UnktUmVSSmZESnh0bDEtbUhESFJSOTE5R0h6Z09BSE5IMWx4dHh0RUlMbTJJeDFCTmM1MEhNNERnVk9VbllCczE5Z1lnWTdHZXZDc1BKSlRhakN6MVdKRjUxVmF5YUV6ZUlFZVo1ZmhsTVhKUG8xcno3RGgwSmdvbk9QNWtnM2RzRjNDWjQ3R1l3?oc=5","date":"2026-01-12","type":"pipeline","source":"Business Wire","summary":"Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan - Business Wire","headline":"Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Out","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPYUFPVGEyNzJzLVd3bXVBMlFVWVpxNHJVeHM4NlItUUpUajR2QkZyMF95YzBMWktZaWFHNG5kOG5ZWWl2aXUtZHRHR2J2ck1YTUVTQ0NFQVJPX2I1eXFqZ3J1dllHZzIzTGR3NUVXS1h2dnRmTDNwblQ4T2M4WjM5UlRCczRwa3lMRlY5UEo5NzNVMzVfczhyNWNKM1Z4QQ?oc=5","date":"2025-12-22","type":"pipeline","source":"Seeking Alpha","summary":"Regencell Bioscience is the top performing pharma stock YTD (RGC:NASDAQ) - Seeking Alpha","headline":"Regencell Bioscience is the top performing pharma stock YTD (RGC:NASDAQ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxPaklRdGxQMnVJWWh4cnZ0Wjd6N18xZzE3bmNYN3NDdlRLLThxZC13T1QzQVY1MVF0SHRQOEp0NFVJRlZNSGpUVmpHWncySE5hbE5aWHN1YUFPUHZpZElzZTZKcGFHUGJqVWQ2c241clpnblk3MlRwclprOFEwMWt0RWotN2JlSVBtaFhCdWZVUXlGdEVKTFE?oc=5","date":"2025-09-05","type":"regulatory","source":"Mugglehead Magazine","summary":"Nuvation Bio stock climbs 16.67% on FDA approval of lung cancer drug - Mugglehead Magazine","headline":"Nuvation Bio stock climbs 16.67% on FDA approval of lung cancer drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQWEVNcVlPUjgyZ200UF9UcUdoam1qZ0IwMm1lOWpCWjJIWXVudWxqQ08zRUtvV1NqcjkxNnNCXzhabDItdWNfVWtwQXpDalFDeThwc3V4M0FCcDNzSm80Y1dKaGhTWUdKdGJxOENkLXotb3VZQnBPanktR3NjdHZQRWpMMXVrZXhsVGlhQkp3Ni1zcm5zYVBNYTRJbjNNQnRrRlYzSVNEVXQ1NVFPczk5bV9iSTFoZkJqb1ZCSmhn?oc=5","date":"2025-06-11","type":"regulatory","source":"Reuters","summary":"US FDA approves Nuvation Bio's rare lung cancer drug - Reuters","headline":"US FDA approves Nuvation Bio's rare lung cancer drug","sentiment":"positive"}],"patents":[{"drugName":"NUV-422","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"NUV-744","drugSlug":"generic-name-not-publicly-disclosed","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":5,"phaseCounts":{"phase_2":1,"marketed":1,"phase_1":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bristol Myers Squibb","Merck & Co.","Roche Holding"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar","revenue":62902000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":62902000,"period":"2025-12-31"},{"value":7873000,"period":"2024-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":115106000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-204627000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":594822000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":4.53,"previousClose":4.51,"fiftyTwoWeekHigh":9.75,"fiftyTwoWeekLow":1.57,"fiftyTwoWeekRange":"1.57 - 9.75","fiftyDayAverage":5.06,"twoHundredDayAverage":4.7,"beta":1.61,"enterpriseValue":1105392768,"forwardPE":-31.2,"priceToBook":5.13,"priceToSales":25.01,"enterpriseToRevenue":17.57,"enterpriseToEbitda":-5.23,"pegRatio":0,"ebitda":-211324992,"ebitdaMargin":0,"freeCashflow":-115776248,"operatingCashflow":-173427008,"totalDebt":66940000,"debtToEquity":21.9,"currentRatio":6.95,"returnOnAssets":-23.5,"returnOnEquity":-53.2,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":9,"targetMeanPrice":12.33,"targetHighPrice":20,"targetLowPrice":7,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":18.8,"institutionHeldPercent":62.2,"sharesOutstanding":346597289,"floatShares":234798493,"sharesShort":49451100,"shortRatio":9.24,"shortPercentOfFloat":14.2,"epsTrailing":-0.6,"epsForward":-0.14,"revenuePerShare":0.18,"bookValue":0.88,"officers":[{"age":67,"name":"Dr. David T. Hung M.D.","title":"Founder, President, CEO & Chairman"},{"age":58,"name":"Dr. Gary  Hattersley Ph.D.","title":"Chief Scientific Officer"},{"age":54,"name":"Ms. Colleen  Sjogren","title":"Chief Commercial Officer"},{"age":48,"name":"Mr. Philippe Pierre Sauvage","title":"CFO & Principal Financial Officer"},{"age":47,"name":"Mr. Moses  Makunje CPA","title":"VP of Finance and Principal Accounting & Financial Officer"},{"age":null,"name":"Dr. Stephen  Dang Ph.D.","title":"Chief Legal Officer & Corporate Secretary"},{"age":60,"name":"Ms. Stacy  Markel","title":"Chief People Officer"},{"age":55,"name":"Dr. David C. Hanley Ph.D.","title":"Chief Technical Operations Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.nuvationbio.com","phone":"332 208 6102"}}